@prefix this: <http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4> .
@prefix sub: <http://purl.org/np/RAaNyCekmldrtbtpjnkO835gR_6Se5OpWFFrQfJT1UPx4#> .
@prefix schema: <https://schema.org/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix nt: <https://w3id.org/np/o/ntemplate/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix orcid: <https://orcid.org/> .
@prefix bl: <https://w3id.org/biolink/vocab/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_1926> bl:category bl:Disease .
  
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_1926>;
    rdf:predicate bl:treats;
    rdf:subject <https://identifiers.org/drugbank:DB09039>;
    a rdf:Statement;
    rdfs:label "cerdelga is indicated for the long term treatment of adult patients with gaucher disease type 1 gd1 who are cyp2d6 extensive metabolizers ems intermediate metabolizers ims or poor metabolizers pms as detected by an fda cleared test see dosage and administration 2 1 cerdelga is a glucosylceramide synthase inhibitor indicated for the long term treatment of adult patients with gaucher disease type 1 who are cyp2d6 extensive metabolizers ems intermediate metabolizers ims or poor metabolizers pms as detected by an fda cleared test 1 limitations of use cyp2d6 ultra rapid metabolizers may not achieve adequate concentrations of cerdelga to achieve a therapeutic effect 1 a specific dosage cannot be recommended for cyp2d6 indeterminate metabolizers 1 limitations of use patients who are cyp2d6 ultra rapid metabolizers urms may not achieve adequate concentrations of cerdelga to achieve a therapeutic effect see clinical studies 14 a specific dosage cannot be recommended for those patients whose cyp2d6 genotype cannot be determined indeterminate metabolizers see clinical studies 14";
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
    bl:provided_by <https://w3id.org/um/NeuroDKG>;
    bl:relation schema:TreatmentIndication .
  
  <https://identifiers.org/drugbank:DB09039> bl:category bl:Drug .
}

sub:provenance {
  sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}

sub:pubinfo {
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
    npx:hasSignature "ETYCD+lirERQF6b0Ei6c6patvEaJ9gFUT+twB6KJmuH22oOL5L4gPyH1dr8AlkH0cpgLmmS+3ETBypfg4UhEKVBPVJ+dvSApBSa4po6WF7VI4BCSa+s2AfHwJQKxo2/wY32tV9erK/V/wwzt1vSIerAJz1gE78DgvqJU+A8hxqs=";
    npx:hasSignatureTarget this: .
  
  this: dct:created "2021-06-12T14:23:10.024+02:00"^^xsd:dateTime;
    dct:creator orcid:0000-0002-1468-3557;
    nt:wasCreatedFromProvenanceTemplate <http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM>;
    nt:wasCreatedFromPubinfoTemplate <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM>;
    nt:wasCreatedFromTemplate <http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs> .
}